MSB · ASX

Mesoblast Limited (ASX:MSB)

AU$1.85

 0.055 (3.064%)
ASX:Live
01/05/2025 12:21:12 PM
HALO Ords HALO 200 HALO 100 GROWTH AUS EMA 125 Breakdown +2
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

MSB Overview

MSB Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Strong

Growth

Earnings

Neutral

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Weak

About MSB

Website

Mesoblast Limited

Telephone

61.3.9639.6036

Address

Level 38 55 Collins Street Melbourne, Victoria (VIC) 3000

Description

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

MSB Price Chart

Key Stats

Market Cap

AU$2.34B

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.88 - 3.37

Trade Value (12mth)

US$1,928,265.00

1 week

0.28%

1 month

-7.24%

YTD

-46.42%

1 year

63.18%

All time high

9.42

Key Fundamentals

EPS 3 yr Growth

-42.50%

EBITDA Margin

-917.70%

Operating Cashflow

-$56m

Free Cash Flow Return

-9.50%

ROIC

-15.00%

Interest Coverage

-2.40

Quick Ratio

1.20

Other Data

Shares on Issue (Fully Dilluted)

1142m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

USD

Short Sell (% of issue)

5.49

MSB Announcements

Latest Announcements

Date Announcements

30 April 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

29 April 25

Director Appointment

×

Director Appointment

29 April 25

Initial Director's Interest Notice

×

Initial Director's Interest Notice

24 April 25

Appendix 3Y for Gregory George

×

Appendix 3Y for Gregory George

17 April 25

Mesoblast Extends Ryoncil Payer Coverage To 104M US Lives

×

Mesoblast Extends Ryoncil Payer Coverage To 104M US Lives

14 April 25

Notification regarding unquoted securities - MSB

×

Notification regarding unquoted securities - MSB

14 April 25

Application for quotation of securities - MSB

×

Application for quotation of securities - MSB

14 April 25

Notification regarding unquoted securities - MSB

×

Notification regarding unquoted securities - MSB

14 April 25

Notification of cessation of securities - MSB

×

Notification of cessation of securities - MSB

08 April 25

Notification regarding unquoted securities - MSB

×

Notification regarding unquoted securities - MSB

08 April 25

Appendix 3Y - Silviu Itescu, Eric Rose and Philip Krause

×

Appendix 3Y - Silviu Itescu, Eric Rose and Philip Krause

04 April 25

Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs

×

Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs

03 April 25

Meeting Requested with FDA on Revascor Accelerated Approval

×

Meeting Requested with FDA on Revascor Accelerated Approval

31 March 25

First Children To Begin Treatment, Medicaid Covers Ryoncil

×

First Children To Begin Treatment, Medicaid Covers Ryoncil

27 March 25

Ryoncil Is Now Available For Purchase In The United States

×

Ryoncil Is Now Available For Purchase In The United States

14 March 25

Ryoncil Published in All Four Major Drug Pricing Compendia

×

Ryoncil Published in All Four Major Drug Pricing Compendia

13 March 25

Appendix 3Y for Gregory George

×

Appendix 3Y for Gregory George

13 March 25

CEO Presentation at ISCT North America

×

CEO Presentation at ISCT North America

12 March 25

CEO to Deliver Featured Presentation at ISCT North America

×

CEO to Deliver Featured Presentation at ISCT North America

07 March 25

Appendix 3Y for Eric Rose

×

Appendix 3Y for Eric Rose

07 March 25

Notification regarding unquoted securities - MSB

×

Notification regarding unquoted securities - MSB

07 March 25

Appendix 3Y for Jane Bell

×

Appendix 3Y for Jane Bell

07 March 25

Appendix 3Y and replacement Appendix 3X for Gregory George

×

Appendix 3Y and replacement Appendix 3X for Gregory George

06 March 25

Mesoblast Added to S&P ASX200 Index

×

Mesoblast Added to S&P ASX200 Index

28 February 25

ZSP: Arcadium Lithium PLC to be removed from the S&P/ASX 200

×

ZSP: Arcadium Lithium PLC to be removed from the S&P/ASX 200

MSB Fundamentals

Per Share Records

Historical data

Forecast data

USD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.13 -0.11 -0.09 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.13 -0.11 -0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock 13.8 21.3 15.2 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.11 -0.08 -0.05 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.11 -0.09 -0.06 Lock Lock Lock
     Growth % Lock Lock Lock Lock 22.1 30.5 40.2 Lock Lock Lock
     Yield % Lock Lock Lock Lock -25.1 -12.3 -8.7 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.73 0.58 0.42 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock -0.12 -0.09 -0.08 Lock Lock Lock
     Growth % Lock Lock Lock Lock -9,660.3 26.3 4.8 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 684 779 987 Lock Lock Lock
Basic m Lock Lock Lock Lock 684 779 987 Lock Lock Lock

Financial Records

Historical data

Forecast data

USD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 10 8 6 Lock Lock Lock
     Growth % Lock Lock Lock Lock 37.4 -26.5 -21.3 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 60 53 49 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -21 -20 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock 18.7 1.5 51.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock -201.2 -269.7 -166.3 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 301 370 266 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -76 -69 -54 Lock Lock Lock
     Growth % Lock Lock Lock Lock 27.4 9.8 21.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -746.2 -915.7 -917.7 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 4 4 5 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -81 -73 -59 Lock Lock Lock
     Growth % Lock Lock Lock Lock 26.2 9.7 19.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -789.1 -970.5 -996.8 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -92 -86 -89 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 -4 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -91 -82 -88 Lock Lock Lock
     Growth % Lock Lock Lock Lock 7.6 10.4 -7.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -894.6 -1,091.7 -1,490.3 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -72 -69 -56 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock -4 81 48 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -72 -70 -56 Lock Lock Lock
     Growth % Lock Lock Lock Lock 33.5 3.4 19.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock -7.1 -9.3 -9.5 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 60 71 63 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 750 669 669 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 99 106 102 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock 46 45 56 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 253 168 189 Lock Lock Lock
Equity $m Lock Lock Lock Lock 524 507 471 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 596 608 583 Lock Lock Lock
     Growth % Lock Lock Lock Lock -5.6 2.1 -4.2 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -12.2 -12.2 -13.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -17.4 -16.1 -18.7 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -12.4 -12.0 -9.8 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -14.8 -13.7 -15.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -11.6 -11.6 -9.5 Lock Lock Lock

Ratios Records

Historical data

Forecast data

USD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -4.4 -3.4 -2.4 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock -0.6 -0.7 -1.0 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock 8.9 8.9 11.9 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 1.4 1.9 1.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 1.4 1.9 1.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 86.6 87.3 72.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -139.9 -165.0 -76.1 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 2.2 1.3 0.4 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.5 0.2 0.5 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 238.4 271.4 117.5 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -896.9 -1,141.3 -1,508.1 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -12.2 -12.8 -13.3 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -12.2 -12.2 -13.1 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.4 1.3 1.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -17.4 -16.1 -18.7 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -17.4 -16.1 -18.7 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 166.6 276.8 848.7 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 166.6 276.8 848.7 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 256.8 282.5 310.8 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -90.2 -5.7 537.9 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

5.49%

Value ($M)

119

Prior Change

N/A

7 Day Change

0.10%

1 Month Change

0.50%

3 Month Change

3.70%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

MSB Shortsell

Frequently Asked Questions

The current share price of Mesoblast Limited (MSB:ASX) is AU$1.85.
The 52-week high share price for Mesoblast Limited (MSB:ASX) is AU$3.37.
The 52-week low share price for Mesoblast Limited (MSB:ASX)? is AU$0.88.
Mesoblast Limited (MSB:ASX) does not pay a dividend.
Mesoblast Limited (MSB:ASX) does not pay a dividend.
Mesoblast Limited (MSB:ASX) has a franking level of 0.0%.
Mesoblast Limited (MSB:ASX) is classified in the Healthcare.
The current P/E ratio for Mesoblast Limited (MSB:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.